https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3AInsulin_analog%2F16%2FenTranslations:Insulin analog/16/en - Revision history2026-07-10T09:19:47ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Insulin_analog/16/en&diff=130152&oldid=prevFuzzyBot: Importing a new version from external source2024-03-19T08:49:44Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>==Carcinogenicity==<br />
All insulin analogs must be tested for [[carcinogenicity]], as insulin engages in cross-talk with [[Insulin-like growth factor|IGF]] pathways, which can cause abnormal cell growth and tumorigenesis. Modifications to insulin always carry the risk of unintentionally enhancing IGF signalling in addition to the desired pharmacological properties. There has been concern with the mitogenic activity and the potential for carcinogenicity of glargine. Several epidemiological studies have been performed to address these issues. Recent study result of the 6.5 years Origin study with glargine have been published.</div>FuzzyBot